中文摘要：

目的：依据权重配方法结合治疗非酒精性脂肪性肝病（nonalcoholic fatty liver disease,NAFLD）的药效,筛选降脂颗粒组分配比最优方案。方法：降脂颗粒中5味药的提取物,按权重配方设计表U6（35）配制成3水平5味药共6个配伍组（A、B、C、D、E、F）。雄性Wistar大鼠,随机分为空白组（K）、模型组（M）、降脂颗粒6个配伍组（A～F）和辛伐他汀组（S）。K组给予普通饲料,其余予高脂饲料。造模同时A～F和S组给予相应药物灌胃,K、M组予生理盐水,持续6周。收集各组大鼠肝组织和血清,检测血清ALT、AST、HDL、LDL和肝组织甘油三酯（TG）含量,分析肝脏组织病理学变化。结果：M组大鼠肝细胞明显脂肪变性,A～F组与S组大鼠肝组织均有不同程度改善,且A～F组优于S组。相对于K组,M组大鼠ALT、AST升高;A～F组与M组相比ALT、AST水平下调,D、E组下调趋势明显,S组无改善。M组大鼠LDL升高,C、E组LDL水平显著降低。M组大鼠肝组织TG显著升高,A～E和S组TG均显著下调,其中A、C、E组优于S组,E组作用最明显。结论：降脂颗粒各组分配伍组对大鼠NAFLD模型均有疗效,其中优选出E组疗效最显著,可作为研发治疗NAFLD疗效更优的中成药的基础。

英文摘要：

Objective：Based on weighed modification method and therapeutic efficacy for non-alcoholic fatty liver disease（NAFLD）,this study aims to select out the optimal compatibility of Jiangzhi granula components.Methods：According to weighed modification table U6（35）,5 herbal extracts of Jiangzhi granula（gynostemma,cuspidatum,capillaris,salvia,lotus）,were combined into compatibility groups（named A,B,C,D,E,F） based on 3 does levels of 5 herbs.Male Wistar rats,randomly divided into control group（K）,model group（M）,6 Jiangzhi granula compatibility groups（A~F） and simvastatin group（S）.Rats in M and treatment group were fed with high fat diet.For A~F and S group,therapeutic interventions were administrated intragastricly in the meantime for 6 weeks.Indices of treatment efficacy including serum ALT,AST,HDL,LDL,liver TG concentration,as well as liver pathology were measured.Results：HE stain of liver tissues showed apparent hepatosteatosis in M group,which was improved more in A~F than in S group.Serum ALT,AST in M increased,while down-regulated in Jiangzhi granula combination groups,and the trend was higher in D,E group.Compared with K,serum LDL in M group was significantly higher,C,E group reduced LDL level obviously.Liver TG increased in M group,TG level all decreased in A~E and S group,and E group showed the most significant effect.Conclusion：All 6 groups of Jiangzhi granula components combination have therapeutic effect for rat NAFLD model.Especially group E has the best response,which might be the basis of developing a new Chinese medicine with better efficacy and quality guarantee.